Pub Date : 2013-10-01DOI: 10.1586/17469872.2013.835923
M. Andreassi, R. Bilenchi
Pimecrolimus is a drug belonging to the class of macrolactamic immunosuppressants, similar to tacrolimus, and has been employed mainly in the treatment of atopic dermatitis, but is also active in other skin diseases, including genital lichen sclerosus (LS). The safety profile of pimecrolimus was the subject of special attention by the US FDA, which in 2005 issued a Public Health Advisory on the potential risk of cancer associated with the use of topical calcineurin inhibitors. However, many scientific societies have criticized the FDA note, referring to the vast literature on the subject in which there is no evidence available that topical use of the drug is dangerous. Patients with LS, of both sexes, may develop genital squamous cell carcinoma. This event, however, is not a contraindication to the use of pimecrolimus.
{"title":"Topical pimecrolimus in the treatment of genital lichen sclerosus","authors":"M. Andreassi, R. Bilenchi","doi":"10.1586/17469872.2013.835923","DOIUrl":"https://doi.org/10.1586/17469872.2013.835923","url":null,"abstract":"Pimecrolimus is a drug belonging to the class of macrolactamic immunosuppressants, similar to tacrolimus, and has been employed mainly in the treatment of atopic dermatitis, but is also active in other skin diseases, including genital lichen sclerosus (LS). The safety profile of pimecrolimus was the subject of special attention by the US FDA, which in 2005 issued a Public Health Advisory on the potential risk of cancer associated with the use of topical calcineurin inhibitors. However, many scientific societies have criticized the FDA note, referring to the vast literature on the subject in which there is no evidence available that topical use of the drug is dangerous. Patients with LS, of both sexes, may develop genital squamous cell carcinoma. This event, however, is not a contraindication to the use of pimecrolimus.","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83142064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-10-01DOI: 10.1586/17469872.2013.835925
W. Hoetzenecker, E. Guenova, M. Moehrle
{"title":"Banana leaves: an alternative wound dressing material?","authors":"W. Hoetzenecker, E. Guenova, M. Moehrle","doi":"10.1586/17469872.2013.835925","DOIUrl":"https://doi.org/10.1586/17469872.2013.835925","url":null,"abstract":"","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75479791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-10-01DOI: 10.1586/17469872.2013.835922
I. Puzanov, J. Wolchok, P. Ascierto, O. Hamid, K. Margolin
Until recently, there were few treatment options for patients with advanced or metastatic melanoma associated with significant increases in overall survival. Of these, patients with disease that has metastasized to the brain have a particularly poor prognosis and generally ineffective treatment options. Recent advances in immuno-oncology have led to the approval of ipilimumab, an antibody that blocks cytotoxic T-lymphocyte antigen-4 to augment antitumour T-cell responses, and vemurafenib, a BRAF kinase inhibitor. These agents, along with others on the horizon, are promising treatment options for patients with melanoma and CNS involvement. Here we review the data generated to date in patients with melanoma and brain metastases and suggest the direction that future studies may take to optimize outcomes in this subpopulation of patients.
{"title":"Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases","authors":"I. Puzanov, J. Wolchok, P. Ascierto, O. Hamid, K. Margolin","doi":"10.1586/17469872.2013.835922","DOIUrl":"https://doi.org/10.1586/17469872.2013.835922","url":null,"abstract":"Until recently, there were few treatment options for patients with advanced or metastatic melanoma associated with significant increases in overall survival. Of these, patients with disease that has metastasized to the brain have a particularly poor prognosis and generally ineffective treatment options. Recent advances in immuno-oncology have led to the approval of ipilimumab, an antibody that blocks cytotoxic T-lymphocyte antigen-4 to augment antitumour T-cell responses, and vemurafenib, a BRAF kinase inhibitor. These agents, along with others on the horizon, are promising treatment options for patients with melanoma and CNS involvement. Here we review the data generated to date in patients with melanoma and brain metastases and suggest the direction that future studies may take to optimize outcomes in this subpopulation of patients.","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87991335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-10-01DOI: 10.1586/17469872.2013.838513
E. Bagatin, Livia de Vasconcelos Nasser Caetano, J. M. Soares
Ultrasound imaging has been increasingly used in dermatologic research over the past four decades. This paper aims to review its use as a disease severity and treatment efficacy assessment tool, with emphasis on the past five years. Quantitative parameters such as skin thickness, overall echogenicity, echogenicity distribution, dermal–subcutaneous interface length or area are used. The authors review skin aging, cellulite, striae, fillers, scleroderma, hypertrophic scar, wounds and psoriasis studies, and discuss correlation between sonographic findings and clinical assessment and/or validated scores. Data are still insufficient to support ultrasound imaging use as an unique efficacy assessment method in a trial, but favor that it is a valuable adjuvant assessment tool that brings objectiveness to subjective clinical assessment. Further studies and technology improvement will expand its applications in dermatology.
{"title":"Ultrasound and dermatology: basic principles and main applications in dermatologic research","authors":"E. Bagatin, Livia de Vasconcelos Nasser Caetano, J. M. Soares","doi":"10.1586/17469872.2013.838513","DOIUrl":"https://doi.org/10.1586/17469872.2013.838513","url":null,"abstract":"Ultrasound imaging has been increasingly used in dermatologic research over the past four decades. This paper aims to review its use as a disease severity and treatment efficacy assessment tool, with emphasis on the past five years. Quantitative parameters such as skin thickness, overall echogenicity, echogenicity distribution, dermal–subcutaneous interface length or area are used. The authors review skin aging, cellulite, striae, fillers, scleroderma, hypertrophic scar, wounds and psoriasis studies, and discuss correlation between sonographic findings and clinical assessment and/or validated scores. Data are still insufficient to support ultrasound imaging use as an unique efficacy assessment method in a trial, but favor that it is a valuable adjuvant assessment tool that brings objectiveness to subjective clinical assessment. Further studies and technology improvement will expand its applications in dermatology.","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89824567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-01DOI: 10.1586/17469872.2013.814854
E. Moscarella, I. Zalaudek, G. Albertini, A. Lallas, C. Longo, G. Argenziano
71st Meeting of the American Academy of DermatologyMiami Beach, FL, USA, 1–5 March 2013The 71st meeting of the American Academy of Dermatology took place in Miami Beach from 1st to 5th March 2013. The meeting was a big success in terms of scientific output and number of participants, being the most attended meeting in the history of the Academy up to now. The scientific sessions covered basically all the fields of dermatology, encompassing the newest updates from oncologic to cosmetic dermatology. Herein, we focus on cutaneous oncology sessions, including melanoma and non-melanoma skin cancer, resuming both diagnostic and therapeutic updates with special attention to skin cancer prevention and the fascinating frontiers of the new available treatments.
{"title":"Meeting of the american academy of dermatology","authors":"E. Moscarella, I. Zalaudek, G. Albertini, A. Lallas, C. Longo, G. Argenziano","doi":"10.1586/17469872.2013.814854","DOIUrl":"https://doi.org/10.1586/17469872.2013.814854","url":null,"abstract":"71st Meeting of the American Academy of DermatologyMiami Beach, FL, USA, 1–5 March 2013The 71st meeting of the American Academy of Dermatology took place in Miami Beach from 1st to 5th March 2013. The meeting was a big success in terms of scientific output and number of participants, being the most attended meeting in the history of the Academy up to now. The scientific sessions covered basically all the fields of dermatology, encompassing the newest updates from oncologic to cosmetic dermatology. Herein, we focus on cutaneous oncology sessions, including melanoma and non-melanoma skin cancer, resuming both diagnostic and therapeutic updates with special attention to skin cancer prevention and the fascinating frontiers of the new available treatments.","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74900119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-01DOI: 10.1586/17469872.2013.814869
G. Fogarty, A. Guminski, K. Shannon
{"title":"How important is multidisciplinary treatment of melanoma metastases","authors":"G. Fogarty, A. Guminski, K. Shannon","doi":"10.1586/17469872.2013.814869","DOIUrl":"https://doi.org/10.1586/17469872.2013.814869","url":null,"abstract":"","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85433824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-01DOI: 10.1586/17469872.2013.814902
Sara K. Story, L. Geskin
. Over the last 15 years, the number of therapies for CTCL has grown rapidly and continues to do so as new medications are enter-ing clinical trials and seeking US FDA approval. Adverse events (AEs) related to a new therapy sometimes become the treatment-limiting factor. Fortunately, AEs for many medications can be suc-cessfully managed, allowing for contin-ued use and benefit from therapy. Here, we discuss the management of common AEs of several topical and systemic medi -cations frequently used in the treatment of CTCL.
{"title":"Managing adverse effects of cutaneous T-cell lymphoma treatment with supportive care measures","authors":"Sara K. Story, L. Geskin","doi":"10.1586/17469872.2013.814902","DOIUrl":"https://doi.org/10.1586/17469872.2013.814902","url":null,"abstract":". Over the last 15 years, the number of therapies for CTCL has grown rapidly and continues to do so as new medications are enter-ing clinical trials and seeking US FDA approval. Adverse events (AEs) related to a new therapy sometimes become the treatment-limiting factor. Fortunately, AEs for many medications can be suc-cessfully managed, allowing for contin-ued use and benefit from therapy. Here, we discuss the management of common AEs of several topical and systemic medi -cations frequently used in the treatment of CTCL.","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89321099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-01DOI: 10.1586/17469872.2013.814864
M. Jinnin
Scleroderma is one of the autoimmune diseases characterized by tissue fibrosis of the skin and internal organs. The understanding of its pathogenesis and the development of new diagnostic tools or effective therapeutic approaches are urgent.miRNAs 19–25 nucleotides in length, directly bind to complementary sequences in the three prime untranslated regions (3´ UTRs) of target mRNAs, leading to the modulation of gene expression. Various miRNAs including miR-29, -206, -125b, -21, -145, -196, -150, -129-5p, -92a, and let-7g may be associated with the fibrosis in scleroderma via regulating the expression of collagens, integrins or matrix metalloproteinases. In addition, serum levels of miR-29a, -196a, -150, -92a, and -142-3p are correlated with the diagnosis or disease activity of this disease. On the other hand, miRNA treatment may become a promising therapeutic strategy in various human diseases. Systemic administration of let-7-attenuated bleomycin-induced mice skin fibrosis, suggesting an antifibrotic effe...
{"title":"Contribution of miRNAs to the pathogenesis of scleroderma and targeting them for the diagnosis and treatment","authors":"M. Jinnin","doi":"10.1586/17469872.2013.814864","DOIUrl":"https://doi.org/10.1586/17469872.2013.814864","url":null,"abstract":"Scleroderma is one of the autoimmune diseases characterized by tissue fibrosis of the skin and internal organs. The understanding of its pathogenesis and the development of new diagnostic tools or effective therapeutic approaches are urgent.miRNAs 19–25 nucleotides in length, directly bind to complementary sequences in the three prime untranslated regions (3´ UTRs) of target mRNAs, leading to the modulation of gene expression. Various miRNAs including miR-29, -206, -125b, -21, -145, -196, -150, -129-5p, -92a, and let-7g may be associated with the fibrosis in scleroderma via regulating the expression of collagens, integrins or matrix metalloproteinases. In addition, serum levels of miR-29a, -196a, -150, -92a, and -142-3p are correlated with the diagnosis or disease activity of this disease. On the other hand, miRNA treatment may become a promising therapeutic strategy in various human diseases. Systemic administration of let-7-attenuated bleomycin-induced mice skin fibrosis, suggesting an antifibrotic effe...","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79458537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-01DOI: 10.1586/17469872.2013.814858
T. Mubki, Omar Shamsaldeen, K. McElwee, J. Shapiro
Female pattern hair loss (FPHL) is the most common cause of hair loss in women. It has a greater psychosocial morbidity than that of male pattern hair loss. The clinical presentation of FPHL is distinctive with hair thinning usually confined to the crown region of the scalp. The frontal hair line is usually spared; however, it can be affected in some patients. Miniaturization of terminal scalp hair and shortening of the anagen growth phase of the hair cycle results in growth of thinner and shorter hair fibers. Diagnosis is usually made clinically. Recent advances in digital image analysis has increased the use of dermatoscopy in the diagnosis of FPHL and as a consequence, reduced the need for doing skin biopsies. Many medical and surgical treatments are currently available with various success rates. In this review article, we discuss the major recent advances in the diagnosis and management of FPHL.
{"title":"An update on diagnosis and treatment of female pattern hair loss","authors":"T. Mubki, Omar Shamsaldeen, K. McElwee, J. Shapiro","doi":"10.1586/17469872.2013.814858","DOIUrl":"https://doi.org/10.1586/17469872.2013.814858","url":null,"abstract":"Female pattern hair loss (FPHL) is the most common cause of hair loss in women. It has a greater psychosocial morbidity than that of male pattern hair loss. The clinical presentation of FPHL is distinctive with hair thinning usually confined to the crown region of the scalp. The frontal hair line is usually spared; however, it can be affected in some patients. Miniaturization of terminal scalp hair and shortening of the anagen growth phase of the hair cycle results in growth of thinner and shorter hair fibers. Diagnosis is usually made clinically. Recent advances in digital image analysis has increased the use of dermatoscopy in the diagnosis of FPHL and as a consequence, reduced the need for doing skin biopsies. Many medical and surgical treatments are currently available with various success rates. In this review article, we discuss the major recent advances in the diagnosis and management of FPHL.","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81424727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-01DOI: 10.1586/17469872.2013.814905
W. Bakkour, V. Madan
Mohs micrographic surgery (MMS) is a technique that allows examination of all surgical margins of the excised skin lesion. It is a well-established treatment for high-risk basal and squamous cell carcinomas yielding unsurpassed cure rates. MMS is also employed to treat melanomas and certain uncommon tumors such as dermatofibrosarcoma protuberans, microcystic adnexal carcinoma, Merkel cell carcinoma, sebaceous carcinoma, desmoplastic trichoepithelioma, extramammary Paget’s disease and atypical fibroxanthoma. This article will review the evidence for MMS in the management of these less common indications.
{"title":"Mohs micrographic surgery miscellaneous indications","authors":"W. Bakkour, V. Madan","doi":"10.1586/17469872.2013.814905","DOIUrl":"https://doi.org/10.1586/17469872.2013.814905","url":null,"abstract":"Mohs micrographic surgery (MMS) is a technique that allows examination of all surgical margins of the excised skin lesion. It is a well-established treatment for high-risk basal and squamous cell carcinomas yielding unsurpassed cure rates. MMS is also employed to treat melanomas and certain uncommon tumors such as dermatofibrosarcoma protuberans, microcystic adnexal carcinoma, Merkel cell carcinoma, sebaceous carcinoma, desmoplastic trichoepithelioma, extramammary Paget’s disease and atypical fibroxanthoma. This article will review the evidence for MMS in the management of these less common indications.","PeriodicalId":12255,"journal":{"name":"Expert Review of Dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78108443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：